AbCellera Biologics Inc.
ABCL
$3.16
$0.010.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.28% | -11.24% | -36.13% | -107.42% | -192.84% |
| Total Depreciation and Amortization | 112.30% | 110.39% | 220.78% | 118.50% | 13.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -80.16% | -74.07% | -95.84% | -60.04% | 1.90% |
| Change in Net Operating Assets | 26.67% | -295.41% | -196.39% | 81.35% | -90.04% |
| Cash from Operations | -88.82% | -147.41% | -1,908.11% | 23.86% | -131.20% |
| Capital Expenditure | 24.63% | -1.88% | -3.14% | -17.88% | -21.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 269.16% | 238.60% | 199.70% | 129.78% | 111.00% |
| Cash from Investing | 339.09% | 154.91% | 128.70% | 109.29% | 91.26% |
| Total Debt Issued | 19.96% | 24.16% | 95.70% | 2,827.41% | 1,694.35% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 16.61% | -36.30% | -36.30% | -12.99% | 20.41% |
| Repurchase of Common Stock | -46.30% | -46.30% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -53.29% | 40.92% | 29.74% | 33.60% | -81.85% |
| Cash from Financing | 16.58% | 23.30% | 78.56% | 5,356.01% | 1,205.74% |
| Foreign Exchange rate Adjustments | -6,033.33% | -544.31% | 631.30% | 89.23% | 100.22% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 151.40% | 109.06% | 77.15% | 94.85% | 80.23% |